CGEN

Compugen Ltd. is a clinical-stage therapeutic discovery and development company based in Israel. The company utilizes proprietary computational discovery platforms to identify novel drug targets and biological pathways for developing cancer immunotherapies and other therapeutics. Compugen's predictive discovery infrastructure combines bioinformatics, mathematical algorithms, and biological data to systematically identify immune checkpoint regulators and other immune system proteins that may serve as therapeutic targets. The company's pipeline includes antibody-based therapeutic candidates targeting novel immune checkpoints for oncology indications. Compugen has established collaborations and licensing agreements with pharmaceutical companies to co-develop or out-license programs discovered through its platforms. The company's approach aims to identify first-in-class or best-in-class therapeutic candidates by discovering previously unknown or poorly characterized targets before they are validated by competitors. As a discovery-focused biotech company, Compugen generates revenue through collaborations, milestone payments, and potential royalties while advancing its wholly-owned programs through early clinical development.